Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec Nanomedicine Drug Candidate in Ovarian Cancer
Maastricht, The Netherlands, October 25, 2018 / B3C newswire / -- Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for th...




